SPARC and hepatocellular carcinoma: Co-treatment with KPA also decreased the expression of genes (Figure 7I,J), regulating the progression of fibrosis (e.g., COL6A3, AEBP1, SPARC, TNC, LAMB1, BGN) and hepatocellular carcinoma (e.g., COL4A1, COL4A2, TUFT1, VCAN, NID1).